SCHEMBL7746281

SCHEMBL7746281

O=c1c2c([nH]c3ccccc13)-c1ccccc1C2

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 10/20 0.75
CA2 P00918 10/20 0.75
CA4 P22748 10/20 0.75
CA6 P23280 10/20 0.75
CCNT1 O60563 1/20 0.51
CCNB2 O95067 1/20 0.51
CDK1 P06493 1/20 0.51
CCNB1 P14635 1/20 0.51
CCNA2 P20248 1/20 0.51
CDK2 P24941 1/20 0.51
GSK3B P49841 1/20 0.51
CDK9 P50750 1/20 0.51
CCNA1 P78396 1/20 0.51
CDK5 Q00535 1/20 0.51
CDK5R1 Q15078 1/20 0.51
SIRT2 Q8IXJ6 1/20 0.51
CCNB3 Q8WWL7 1/20 0.51
SIRT1 Q96EB6 1/20 0.51
NTRK1 P04629 2/20 0.51
KDR P35968 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2298597 0.86 CA1 (1.00) CA1CA2CA4CA6CCNT1
SCHEMBL29370925 0.86 CA1 (1.00) CA1CA2CA4CA6CCNT1
SCHEMBL2763222 0.78 PARP1 (0.70) CA1CA2CA4CA6CCNT1
SCHEMBL30966003 0.76 KMT2A (0.60) CA1CA2CA4CA6CCNT1
SCHEMBL12126575 0.74 CA1 (0.71) CA1CA2CA4CA6CCNT1
SCHEMBL30063877 0.74 CA1 (0.71) CA1CA2CA4CA6CCNT1
Anthrone SCHEMBL28721809 0.74 MAOA (0.67) CA1CA2CA4CA6CCNT1
SCHEMBL15759621 0.73 CDK1 (0.72) CA1CA2CA4CA6CCNT1
SCHEMBL4627835 0.73 CA1 (0.69) CA1CA2CA4CA6CCNB2
SCHEMBL15133573 0.73 AHR (0.46) CA1CA2CA4CA6CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691983-B2 Specifically substituted benzofuro- and benzothienoquinolines for organic light emitting diodes IDEMITSU KOSAN CO., LTD. (JP) 2023-07-04 US disclosed
EP-2722322-B1 1,3-DI-OXO-INDENE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ANTIVIRAL, ACTIVE INGREDIENT KOREA RES INST CHEMICAL TECH (KR) 2019-06-12 EP disclosed
JP-2001089455-A 5,10-DIHYDRO-11H-INDENO[1,2-B]QUINOLIN-10-ONE DERIVATIVE MARUISHI PHARMACEUTICAL CO LTD 2001-04-03 JP disclosed
JP-2001089455-A 5,10-DIHYDRO-11H-INDENO[1,2-B]QUINOLIN-10-ONE DERIVATIVE MARUISHI PHARMACEUTICAL CO LTD 2001-04-03 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691983-B2 Specifically substituted benzofuro- and benzothienoquinolines for organic light emitting diodes KCNQ2, KCNQ1, KCNQ4 CA1 4851/4885CA2 2954/4885CA4 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.